PBMs Denying Patients Access To Lantus Biosimilars, Says Report

Insulin Glargine Originator Still Has A US Market Share Of Nearly 80%

 
• By Chloe Kent
  
Pack of 5 Lantus pens
Lantus biosimilars have failed to caputre a significant market share • Source: Shutterstock

More from Biosimilars

More from Products